Human CD20 / MS4A1 Full Length Protein, His Tag (Detergent) (SPR verified)
分子別名（Synonym）
MS4A1, CD20, MS4A-1
表達區(qū)間及表達系統(tǒng)（Source）
Human CD20 Full Length Protein, His Tag (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met 1
蛋白結構（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>85% as determined by SDS-PAGE.
制劑（Formulation）
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
運輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
背景介紹
B淋巴細胞抗原CD20（亦稱B淋巴細胞表面抗原B1、白細胞表面抗原Leu-16、四次跨膜結構域亞家族A成員1、MS4A1）是一種活化糖基化磷蛋白。該抗原自前B細胞階段（CD45R+，CD117+）起始表達于所有B細胞表面，其濃度隨細胞成熟度逐步遞增。除發(fā)育首尾階段外，CD20存在于B細胞發(fā)育全程：從晚期前B細胞延伸至記憶B細胞均有表達，但在早期前B細胞、漿母細胞及漿細胞中缺失。該抗原表達于B細胞淋巴瘤、毛細胞白血病、B細胞慢性淋巴細胞白血病及黑色素瘤干細胞表面。其功能雖無已知天然配體，但能介導最佳B細胞免疫應答，特別是針對非T細胞依賴性抗原。學界推測其可能作為鈣離子通道存在于細胞膜上。CD20/MS4A1是單克隆抗體利妥昔單抗、替伊莫單抗以及托西莫單抗的作用靶點，這些抗體藥物治療所有類型B細胞淋巴瘤及白血病均具有活性。CD20/MS4A1缺陷是導致普通可變型免疫缺陷病5型（CVID5）的病因，該病又稱CD20缺陷性抗體缺乏癥，屬于以抗體缺乏、低丙種球蛋白血癥、反復細菌感染及抗原抗體應答缺失為特征的原發(fā)性免疫缺陷病。
關鍵字： CD20;CD20蛋白;CD20重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。